<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39073768</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1755-3245</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Jul</Month><Day>29</Day></PubDate></JournalIssue><Title>Cardiovascular research</Title><ISOAbbreviation>Cardiovasc Res</ISOAbbreviation></Journal><ArticleTitle>COVID-19 related myocardial injury is associated with immune dysregulation in symptomatic patients with cardiac MRI abnormalities.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">cvae159</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/cvr/cvae159</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">While acute cardiovascular complications of COVID-19 are well-described, less is known about longer-term cardiac sequelae. For many individuals with cardiac signs or symptoms arising after COVID-19 infection, the aetiology remains unclear. We examined immune profiles associated with magnetic resonance imaging (MRI) abnormalities in patients with unexplained cardiac injury after COVID-19.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Twenty-one participants (mean age 47 [SD 13] years, 71% female) with long COVID (n=17), raised troponin (n=2), or unexplained new-onset heart failure (n=2), who did not have pre-existing heart conditions or recent steroid/immunosuppression treatment were enrolled a mean 346 (SD 191) days after COVID-19 infection in a prospective observational study. Cardiac MRI and blood sampling for deep immunophenotyping using mass cytometry by time of flight and measurement of proteomic inflammatory markers was performed. Nine of 21 (43%) participants had MRI abnormalities (MRI(+)), including non-ischaemic patterns of late gadolinium enhancement and/or visually overt myocardial oedema in 8 people. One patient had mildly impaired biventricular function without fibrosis or oedema, and 2 had severe left ventricular impairment. MRI(+) individuals had higher blood CCL3, CCL7, FGF-23 and CD4 Th2 cells, and lower CD8 T effector memory (TEM) cells, than MRI(-). Cluster analysis revealed lower expression of inhibitory receptors PD1 and TIM3 in CD8 TEM cells from MRI(+) patients than MRI(-) patients, and functional studies of CD8 T &#x3b1;&#x3b2; cells showed higher proportions of cytotoxic granzyme B+ secreting cells upon stimulation. CD8 TEM cells and CCL7 were the strongest predictors of MRI abnormalities in a LASSO regression model (composite AUC 0.96, 95%CI 0.88-1.0). CCL7 was correlated with diffuse myocardial fibrosis/oedema detected by quantitative T1 mapping (r=0.47, p=0.04).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">COVID-19 related cardiac injury in symptomatic patients with non-ischaemic myocarditis-like MRI abnormalities is associated with immune dysregulation, including decreased peripheral CD8 TEM cells and increased CCL7, persisting long after the initial infection.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>&#x106;orovi&#x107;</LastName><ForeName>Andrej</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Cardiorespiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xiaohui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Section of Cardiorespiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Section of Cardiorespiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newland</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Section of Cardiorespiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gopalan</LastName><ForeName>Deepa</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8079-205X</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Cambridge University Hospitals NHS Trust, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Section of Cardiorespiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giakomidi</LastName><ForeName>Despina</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Section of Cardiorespiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shanna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Section of Cardiorespiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yarkoni</LastName><ForeName>Natalia S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Cell Phenotyping Hub, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wall</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Section of Cardiorespiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peverelli</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Section of Cardiorespiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sriranjan</LastName><ForeName>Rouchelle</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Section of Cardiorespiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallo</LastName><ForeName>Arianna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Cardiorespiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graves</LastName><ForeName>Martin J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sage</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Cardiorespiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sithole</LastName><ForeName>Nyarie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Infectious Diseases, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Section of Cardiorespiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudd</LastName><ForeName>James H F</ForeName><Initials>JHF</Initials><AffiliationInfo><Affiliation>Section of Cardiorespiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallat</LastName><ForeName>Ziad</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Section of Cardiorespiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Tian X</ForeName><Initials>TX</Initials><AffiliationInfo><Affiliation>Section of Cardiorespiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nus</LastName><ForeName>Meritxell</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6378-8910</Identifier><AffiliationInfo><Affiliation>Section of Cardiorespiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarkin</LastName><ForeName>Jason M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-9132-120X</Identifier><AffiliationInfo><Affiliation>Section of Cardiorespiratory Medicine, Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cardiovasc Res</MedlineTA><NlmUniqueID>0077427</NlmUniqueID><ISSNLinking>0008-6363</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>29</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>29</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>29</Day><Hour>11</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39073768</ArticleId><ArticleId IdType="doi">10.1093/cvr/cvae159</ArticleId><ArticleId IdType="pii">7723296</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>